The more extensive examination of data on the use SGLT2 inhibitors in over 20,000 participants in five trials, shows reduced risk of HF hospitalization and CV and all-cause mortality across a broad range of patients with heart failure, irrespective of LVEF, care setting or concomitant treatment with an MRA or ARNI. The gene discussed is SLC5A2; the disease is heart failure.